BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 38131515)

  • 1. Venetoclax overcomes resistance to all-trans retinoic acid in a variant acute promyelocytic leukemia with TNRC18::RARA fusion.
    Xu J; Li H; Wang Z; Wang M; Li Q; Hang X; Xu J; Ji J; Chen C; Liu Y; Niu T
    Mol Carcinog; 2024 Apr; 63(4):553-557. PubMed ID: 38131515
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relapsed/refractory acute promyelocytic leukemia with RARA-LBD region mutation was salvaged by venetoclax: A case report.
    Li Y; Yu J; Xu Q; Zhang K
    Medicine (Baltimore); 2021 Dec; 100(48):e28076. PubMed ID: 35049232
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differentiation therapy using low-dose venetoclax in a variant acute promyelocytic leukaemia carrying ZBTB16-RARA.
    Li H; Xiang X; Ding H; Yu J; Xu J; Yuan Y; Wu Y
    Br J Haematol; 2022 Dec; 199(5):768-771. PubMed ID: 36169236
    [No Abstract]   [Full Text] [Related]  

  • 4. A novel HNRNPC-RARA fusion in acute promyelocytic leukaemia lacking PML-RARA rearrangement, sensitive to venetoclax-based therapy.
    Liu M; Zhao X; Pan W; Qian Z; Du M; Wang LM; Huang H; Xiao H
    Br J Haematol; 2021 Oct; 195(2):e123-e128. PubMed ID: 34254314
    [No Abstract]   [Full Text] [Related]  

  • 5. Missense mutations in the PML/RARalpha ligand binding domain in ATRA-resistant As(2)O(3) sensitive relapsed acute promyelocytic leukemia.
    Marasca R; Zucchini P; Galimberti S; Leonardi G; Vaccari P; Donelli A; Luppi M; Petrini M; Torelli G
    Haematologica; 1999 Nov; 84(11):963-8. PubMed ID: 10553155
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute Promyelocytic Leukemia with del(6)(p22) and Atypical bcr2 PML::RARA Fusion Transcript: A Case Report.
    Lauricella C; Greco R; Mancini V; Motta V; Ciraolo A; De Canal G; De Paoli E; Paglino G; Guido V; Bonoldi E; Veronese S; Soriani S
    Acta Haematol; 2023; 146(1):58-64. PubMed ID: 36198282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effects of all-trans retinoic acid and arsenic trioxide on tissue factor expression of acute promyelocytic leukemia cells].
    Guo W; Wang H; Zhao W
    Zhonghua Yi Xue Za Zhi; 2000 May; 80(5):327-31. PubMed ID: 11798779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute promyelocytic leukemia with isochromosome 17q and cryptic PML-RARA successfully treated with all-trans retinoic acid and arsenic trioxide.
    Shepshelovich D; Oniashvili N; Parnes D; Klein A; Muchtar E; Yeshaya J; Aviram A; Rabizadeh E; Raanani P
    Cancer Genet; 2015 Nov; 208(11):575-9. PubMed ID: 26471811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of the novel deletion-type PML-RARA mutation associated with the retinoic acid resistance in acute promyelocytic leukemia.
    Hattori H; Ishikawa Y; Kawashima N; Akashi A; Yamaguchi Y; Harada Y; Hirano D; Adachi Y; Miyao K; Ushijima Y; Terakura S; Nishida T; Matsushita T; Kiyoi H
    PLoS One; 2018; 13(10):e0204850. PubMed ID: 30289902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of a rarely reported STAT5B/RARA gene fusion in a young adult with newly diagnosed acute promyelocytic leukemia with resistance to ATRA therapy.
    Peterson JF; He RR; Nayer H; Cuevo RS; Smadbeck JB; Vasmatzis G; Greipp PT; Ketterling RP; Hoppman NL; Baughn LB
    Cancer Genet; 2019 Sep; 237():51-54. PubMed ID: 31447065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PML-RARA transcript levels at the end of induction therapy are associated with prognosis in non-high-risk acute promyelocytic leukaemia with all-trans retinoic acid plus arsenic in front-line therapy: long-term follow-up of a single-centre cohort study.
    Tang FF; Lu SY; Zhao XS; Qin YZ; Liu XH; Jia JS; Wang J; Gong LZ; Jiang Q; Zhao T; Shi HX; Chang YJ; Huang XJ; Jiang H
    Br J Haematol; 2021 Dec; 195(5):722-730. PubMed ID: 34405393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Case of Relapsed/Refractory CD56-Positive Acute Promyelocytic Leukemia, in Which Complete Molecular Remission Was Achieved Following Combination Therapy with Venetoclax and Azacitidine.
    Sekiguchi Y; Tsutsumi H; Gomyo A; Kudo M; Maseki N; Iizaki Y; Kawamura M; Kobayashi K; Nitta H; Noguchi M; Wakita S; Yamaguchi H; Kobayashi H
    Gan To Kagaku Ryoho; 2024 Mar; 51(3):291-297. PubMed ID: 38494811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ZBTB16-RARα-Positive Atypical Promyelocytic Leukemia: A Case Report.
    Pardo Gambarte L; Franganillo Suárez A; Cornago Navascués J; Soto de Ozaeta C; Blas López C; Atance Pasarisas M; Salgado Sánchez RN; Serrano Del Castillo C; Mata Serna R; Velasco Rodríguez D; López-Lorenzo JL; Llamas-Sillero P; Solán Blanco L
    Medicina (Kaunas); 2022 Apr; 58(4):. PubMed ID: 35454359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of concurrent STAT3::RARA and RARA::STAT5b fusions in a variant APL case.
    Tao T; Cen J; Xu C; Chen Y; Cao Y; Gong Y; Zhu M; Chen S; Zhang Q; Yao L
    Mol Carcinog; 2024 Apr; 63(4):558-562. PubMed ID: 38153216
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and genomic characterization of an ATRA-insensitive acute promyelocytic leukemia variant with a FNDC3B::RARB fusion.
    Kirkham JK; Liu YC; Foy SG; Ma J; Gheorghe G; Furtado LV; Popescu MI; Klco JM; Karol SE; Blackburn PR
    Genes Chromosomes Cancer; 2023 Oct; 62(10):617-623. PubMed ID: 37283355
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel treatment of acute promyelocytic leukemia: As₂O₃, retinoic acid and retinoid pharmacology.
    Zhu G
    Curr Pharm Biotechnol; 2013; 14(9):849-58. PubMed ID: 24433507
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute Promyelocytic Leukemia with Rare Genetic Aberrations: A Report of Three Cases.
    Liu G; Liu L; Bartolo DD; Li KY; Li X
    Genes (Basel); 2022 Dec; 14(1):. PubMed ID: 36672788
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Accelerated degradation of PML-retinoic acid receptor alpha (PML-RARA) oncoprotein by all-trans-retinoic acid in acute promyelocytic leukemia: possible role of the proteasome pathway.
    Yoshida H; Kitamura K; Tanaka K; Omura S; Miyazaki T; Hachiya T; Ohno R; Naoe T
    Cancer Res; 1996 Jul; 56(13):2945-8. PubMed ID: 8674046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eradication of acute promyelocytic leukemia-initiating cells by PML/RARA-targeting.
    Nasr R; de Thé H
    Int J Hematol; 2010 Jun; 91(5):742-7. PubMed ID: 20455087
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro response to all-trans retinoic acid of acute promyelocytic leukemias with nonreciprocal PML/RARA or RARA/PML fusion genes.
    Mozziconacci MJ; Liberatore C; Brunel V; Grignani F; Arnoulet C; Ferrucci PF; Fernandez F; Sainty D; Pelicci PG; Birg F; Lafage-Pochitaloff M
    Genes Chromosomes Cancer; 1998 Jul; 22(3):241-50. PubMed ID: 9624536
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.